Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
NCT04008121
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Retinopathy
- Retinal Vein Occlusion
- Diabetic Retinopathy
- Macular Degeneration
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- MediBeacon
- Last updated on ClinicalTrials.gov
- February 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- University of Michigan Kellogg Eye Center · Ann Arbor, MI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.